Law360, New York (April 19, 2010, 2:24 PM ET) -- Biovail Laboratories International SRL has filed a second patent infringement lawsuit to stop generic-drug maker Watson Pharmaceuticals Inc. from launching its own version of antidepressant Aplenzin.
The suit, filed Friday in the U.S. District Court for the Southern District of Florida, comes less than a month after Biovail first sued Watson in February for its attempts to gain regulatory approval for its product.
Watson has filed an abbreviated new drug application with the U.S. Food and Drug Administration to make generic Aplenzin, and sent Biovail Paragraph...
Biovail Files 2nd Suit Over Watson's Aplenzin ANDA
To view the full article, take a free trial now.
